ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents

Screening-methoden unter verwendung eines strukturmodells von fih

Info

Publication number
ATE452204T1
ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
Authority
AT
Austria
Prior art keywords
fih
structural model
structural
screening methods
chemical entity
Prior art date
Application number
AT03758318T
Other languages
English (en)
Inventor
Peter John Ratcliffe
Christopher William Pugh
Christopher Joseph Schofield
Kirsty Sarah Hewitson
Jonathan Mark Elkins
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224102A external-priority patent/GB0224102D0/en
Priority claimed from GB0226598A external-priority patent/GB0226598D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE452204T1 publication Critical patent/ATE452204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Computing Systems (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03758318T 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih ATE452204T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224102A GB0224102D0 (en) 2002-10-16 2002-10-16 Inhibitors
GB0226598A GB0226598D0 (en) 2002-11-14 2002-11-14 Chemical inhibitors
PCT/GB2003/004492 WO2004035812A2 (en) 2002-10-16 2003-10-16 Asparaginyl hydroxylases and modulators thereof

Publications (1)

Publication Number Publication Date
ATE452204T1 true ATE452204T1 (de) 2010-01-15

Family

ID=32109245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758318T ATE452204T1 (de) 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih

Country Status (11)

Country Link
US (1) US7778779B2 (de)
EP (2) EP2156830A1 (de)
JP (1) JP4465276B2 (de)
AT (1) ATE452204T1 (de)
AU (1) AU2003274330B2 (de)
CA (1) CA2502541A1 (de)
DE (1) DE60330587D1 (de)
ES (1) ES2337043T3 (de)
MX (1) MXPA05004033A (de)
PL (1) PL376770A1 (de)
WO (1) WO2004035812A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093411A2 (en) 2004-03-26 2005-10-06 Isis Innovation Limited Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxigenase and methods of using the same
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2012512633A (ja) 2008-12-19 2012-06-07 ヨーロピアン モレキュラー バイオロジー ラボラトリー エンドヌクレアーゼ活性を有するポリペプチド断片、及びそれらの使用
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) * 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (de) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP3345596B1 (de) * 2012-09-21 2021-01-20 Rhode Island Hospital Beta-hydrolase-hemmer zur behandlung von krebs
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US10312653B2 (en) 2015-05-06 2019-06-04 Milwaukee Electric Tool Corporation Hydraulic tool
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
EP3938045A1 (de) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090301A2 (en) 2000-05-17 2001-11-29 Princeton University Crystallizing murg protein, methods of making and using models thereof for inhibition and stimulation via compounds
GB0017323D0 (en) 2000-07-15 2000-08-30 Univ St Andrews Enzyme
WO2002025276A1 (en) 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
AUPR773801A0 (en) * 2001-09-18 2001-10-11 Adelaide Research & Innovation Pty Ltd Asparagine hydroxylation of the cad domain of a hif protein

Also Published As

Publication number Publication date
JP4465276B2 (ja) 2010-05-19
WO2004035812A2 (en) 2004-04-29
EP2156830A1 (de) 2010-02-24
EP1554394B1 (de) 2009-12-16
US20070048728A1 (en) 2007-03-01
WO2004035812A3 (en) 2004-08-19
AU2003274330A1 (en) 2004-05-04
DE60330587D1 (de) 2010-01-28
US7778779B2 (en) 2010-08-17
MXPA05004033A (es) 2005-06-08
EP1554394A2 (de) 2005-07-20
ES2337043T3 (es) 2010-04-20
AU2003274330B2 (en) 2009-06-04
PL376770A1 (pl) 2006-01-09
JP2006504415A (ja) 2006-02-09
CA2502541A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE452204T1 (de) Screening-methoden unter verwendung eines strukturmodells von fih
Livingstone et al. The prediction of hypolimnetic oxygen profiles: a plea for a deductive approach
Wisshak et al. Ocean acidification accelerates reef bioerosion
Yang et al. Carbon and nitrogen dynamics during forest stand development: a global synthesis
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE316147T1 (de) Enzymsensor
DE602005027646D1 (de) Verfahren zum Betrieb eines Navigationssystems zum Melden aktualisierter Teile einer geographischen Datenbank
ATE496141T1 (de) Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems
DE60334365D1 (de) Leistungsverbesserung einer analytenüberwachungsvorrichtung
DE69629292D1 (de) Verfahren zum feststellen der preparationsgüte von objektträgern und proben
ATE507512T1 (de) Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells
ATE532073T1 (de) Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
CN116825220B (zh) 基于连续性分布函数的海洋有机碳降解过程评估方法
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE221657T1 (de) Entstörung durch rheumafaktoren
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
Lu et al. Multivariate calibration models based on the direct analysis of near-infrared single-beam spectra
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
ATE527596T1 (de) Erhalten von konfigurationsdaten für ein datenverarbeitungsgerät
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
Boushaba et al. Dynamics of the ‘echo’effect in a phytoplankton system with nitrogen fixation
DE602006007734D1 (de) Verfahren und system zur echtzeitanalyse von biosensordaten
WO2002072551A3 (en) A non-traumatic model for neurogenic pain
DE50201515D1 (de) Vorrichtung und verfahren zum ersatz von gealtertem entwickler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties